MedTrace Logo

Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation

NCT06565247 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-04

No results posted yet for this study

Summary

In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.

Conditions

Interventions

DRUG

[18F]PSMA-PET

Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.

DEVICE

MRI sequences optimized for prostate cancer examinations

T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital

Sponsors & Collaborators

  • Umeå University

    collaborator OTHER

  • Region Skane

    collaborator OTHER

  • Lund University

    collaborator OTHER

  • Region Västerbotten

    lead OTHER_GOV

Principal Investigators

  • Camilla Thellenberg Karlsson, MD, PhD · Region Västerbotten

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2026-12-31
Completion
2031-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06565247 on ClinicalTrials.gov